A once-daily GLP-1 pill has produced greater weight loss than the current oral standard.
Researchers tested orforglipron in a year-long global phase 3 study.
The drug improves blood sugar control and reduces appetite.
Patients can take it at any time of day.
It removes the fasting requirement linked to oral semaglutide.
More than 1,500 adults with type 2 diabetes joined the trial.
Participants received either orforglipron or oral semaglutide.
Those taking orforglipron lost up to eight percent of body weight.
Semaglutide users lost about five percent.
Orforglipron also delivered stronger glucose reductions.
However, more patients stopped treatment because of stomach-related side effects.
Regulators have not yet approved the drug.
The US review process continues.
Researchers see major potential for tablet therapies.
Pills simplify treatment and may lower long-term costs.
Experts expect future diabetes care to target weight, metabolism, and heart risk together.
